엘앤씨바이오 has raised 60 billion KRW through convertible bonds to invest in 큐렉소, aiming to enhance its market presence in China’s orthopedic sector.
Target Company Overview
엘앤씨바이오, a company specializing in skin and knee cartilage grafts, is intensifying its efforts to penetrate the Chinese market. This initiative involves securing capital from a Korean private equity fund experienced in Chinese investments to support domestic companies aiming to expand in the local market. The strategy includes forming synergies with companies that possess orthopedic product lines.
On December 29, 2023, it was reported that 엘앤씨바이오 issued convertible bonds (CB) totaling 60 billion KRW, primarily to invest in 큐렉소, a company focused on orthopedic surgical robots. Out of the funds raised, approximately 40 billion KRW will be allocated for acquiring shares in 큐렉소, thereby securing a 14% stake and positioning itself as the second-largest shareholder.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in China
The healthcare industry in China is experiencing robust growth, driven by an aging population and increasing demand for advanced medical technologies. The mar
Similar Deals
엘앤씨바이오
invested in
큐렉소
in 2025
in a Series B deal
Disclosed details
Transaction Size: $450M